Analysts Set Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) PT at $32.20

Shares of Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been assigned a consensus rating of “Buy” from the eight analysts that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $32.20.

A number of equities analysts have commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Citigroup boosted their target price on Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the company a “buy” rating in a research note on Monday, March 9th. HC Wainwright lifted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Finally, Chardan Capital lifted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th.

Eyepoint Pharmaceuticals Trading Down 2.9%

Shares of EYPT opened at $13.35 on Friday. The stock has a 50-day moving average price of $14.40 and a 200-day moving average price of $14.60. The company has a market cap of $1.12 billion, a PE ratio of -4.22 and a beta of 1.76. Eyepoint Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last released its earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.79) by ($0.20). The firm had revenue of $0.70 million during the quarter, compared to the consensus estimate of $0.35 million. Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%. As a group, analysts predict that Eyepoint Pharmaceuticals will post -3.01 earnings per share for the current year.

Insider Buying and Selling

In other Eyepoint Pharmaceuticals news, insider Ramiro Ribeiro sold 2,437 shares of the business’s stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 4.46% of the company’s stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Several institutional investors have recently modified their holdings of EYPT. Hsbc Holdings PLC bought a new position in Eyepoint Pharmaceuticals during the 1st quarter valued at about $10,743,000. Janney Montgomery Scott LLC lifted its holdings in Eyepoint Pharmaceuticals by 14.8% in the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock valued at $391,000 after acquiring an additional 3,900 shares during the period. Pictet Asset Management Holding SA purchased a new stake in Eyepoint Pharmaceuticals in the first quarter worth about $141,000. Invesco Ltd. increased its position in Eyepoint Pharmaceuticals by 16.6% in the fourth quarter. Invesco Ltd. now owns 339,004 shares of the company’s stock worth $6,194,000 after buying an additional 48,186 shares in the last quarter. Finally, Virtus Investment Advisers LLC increased its position in Eyepoint Pharmaceuticals by 29.5% in the fourth quarter. Virtus Investment Advisers LLC now owns 16,638 shares of the company’s stock worth $304,000 after buying an additional 3,795 shares in the last quarter. 99.41% of the stock is owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.